| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study
|
Bekker, Adrie
|
|
|
|
1 |
p. e24-e31
|
artikel
|
| 2 |
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial
|
Tomlinson, Mark
|
|
|
|
1 |
p. e42-e51
|
artikel
|
| 3 |
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report
|
Cohen, Stephanie E
|
|
2019
|
|
1 |
p. e43-e50
|
artikel
|
| 4 |
A cry from the heart
|
Burki, Talha
|
|
|
|
1 |
p. e12
|
artikel
|
| 5 |
Actionable adherence monitoring to optimise intervention
|
Haberer, Jessica E
|
|
2017
|
|
1 |
p. e5-e6
nvt p.
|
artikel
|
| 6 |
Addressing inequalities still key to ending HIV/AIDS
|
The Lancet HIV,
|
|
|
|
1 |
p. e1
|
artikel
|
| 7 |
Ageism: the -ism affecting the lives of older people living with HIV
|
Guaraldi, Giovanni
|
|
|
|
1 |
p. e52-e59
|
artikel
|
| 8 |
Age-mixing and the incidence of HIV among young women
|
Gouws, Eleanor
|
|
2017
|
|
1 |
p. e6-e8
nvt p.
|
artikel
|
| 9 |
A HOPE for HIV prevention in virtual MSM communities
|
Cáceres, Carlos F
|
|
2015
|
|
1 |
p. e6-e7
nvt p.
|
artikel
|
| 10 |
A link between antiretrovirals and perinatal outcomes?
|
Mandelbrot, Laurent
|
|
2017
|
|
1 |
p. e3-e5
nvt p.
|
artikel
|
| 11 |
A new index to guide global drug policies
|
Holt, Ed
|
|
|
|
1 |
p. e10-e11
|
artikel
|
| 12 |
Application of artificial intelligence and machine learning for HIV prevention interventions
|
Xiang, Yang
|
|
|
|
1 |
p. e54-e62
|
artikel
|
| 13 |
Approaching the asymptote
|
Kuritzkes, Daniel R
|
|
|
|
1 |
p. e5-e7
|
artikel
|
| 14 |
A public health approach to drug use crucial to ending AIDS
|
Chkhartishvili, Nikoloz
|
|
|
|
1 |
p. e6-e7
|
artikel
|
| 15 |
A reality check for aspirational targets to end HIV
|
Wilson, David P
|
|
2015
|
|
1 |
p. e11-
1 p.
|
artikel
|
| 16 |
Argentina updates HIV laws
|
Daniels, Joe Parkin
|
|
|
|
1 |
p. e11-e12
|
artikel
|
| 17 |
ART regimes and fat: the healing hand wielding the sword
|
Domingo, Pere
|
|
2017
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 18 |
Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis
|
Kelly, Helen
|
|
2018
|
|
1 |
p. e45-e58
|
artikel
|
| 19 |
Better late than never: PrEP in England
|
The Lancet HIV,
|
|
2017
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 20 |
Beyond prevention of mother-to-child HIV transmission
|
Thorne, Claire
|
|
2016
|
|
1 |
p. e5-e6
nvt p.
|
artikel
|
| 21 |
Biometrics and public health surveillance in criminalised and key populations: policy, ethics, and human rights considerations
|
Kavanagh, Matthew M
|
|
2019
|
|
1 |
p. e51-e59
|
artikel
|
| 22 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
|
Boyd, Mark A
|
|
2017
|
|
1 |
p. e13-e20
nvt p.
|
artikel
|
| 23 |
Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study
|
van der Helm, Jannie J
|
|
2014
|
|
1 |
p. e41-e48
nvt p.
|
artikel
|
| 24 |
Combination HIV prevention reduces orphanhood in Uganda
|
Fairlie, Lee
|
|
|
|
1 |
p. e5-e6
|
artikel
|
| 25 |
Community-based HIV testing services in an urban setting in western Kenya: a programme implementation study
|
Truong, Hong-Ha M
|
|
|
|
1 |
p. e16-e23
|
artikel
|
| 26 |
Corrections
|
|
|
2015
|
|
1 |
p. e10-
1 p.
|
artikel
|
| 27 |
Corrections to Lancet HIV 2014; 1: e22, e24
|
|
|
2014
|
|
1 |
p. e12-
1 p.
|
artikel
|
| 28 |
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
|
Ward, Zoe
|
|
|
|
1 |
p. e42-e53
|
artikel
|
| 29 |
COVID-19 antivirals must not affect HIV drug supply
|
Barber, Melissa
|
|
|
|
1 |
p. e7-e9
|
artikel
|
| 30 |
COVID-19 death in people with HIV: interpret cautiously
|
Waters, Laura J
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 31 |
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study
|
Mocroft, Amanda
|
|
2016
|
|
1 |
p. e23-e32
nvt p.
|
artikel
|
| 32 |
Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study
|
Dong, Krista L
|
|
2018
|
|
1 |
p. e35-e44
|
artikel
|
| 33 |
Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study
|
Pereira, Gerson Fernando Mendes
|
|
|
|
1 |
p. e33-e41
|
artikel
|
| 34 |
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
|
Orkin, Chloe
|
|
2018
|
|
1 |
p. e23-e34
|
artikel
|
| 35 |
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial
|
Gupta, Samir K
|
|
2016
|
|
1 |
p. e13-e22
nvt p.
|
artikel
|
| 36 |
Ethics of ART interruption after stem-cell transplantation
|
Sugarman, Jeremy
|
|
2016
|
|
1 |
p. e8-e10
nvt p.
|
artikel
|
| 37 |
Expanding early detection of anal cancer to improve survival
|
Nowak, Rebecca G
|
|
|
|
1 |
p. e5-e6
|
artikel
|
| 38 |
Exploring stigma: HIV in marginalised communities
|
Mitchell, Fiona
|
|
2019
|
|
1 |
p. e14
|
artikel
|
| 39 |
Families still affected by the UK's contaminated blood scandal
|
Mitchell, Fiona
|
|
2019
|
|
1 |
p. e13
|
artikel
|
| 40 |
Family planning for HIV-positive girls and young women
|
Yam, Eileen A
|
|
2017
|
|
1 |
p. e10-e11
nvt p.
|
artikel
|
| 41 |
Fast track to 2030: granularity at a global scale
|
The Lancet HIV,
|
|
2015
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 42 |
Fundación Huésped—combating HIV stigma in Argentina
|
Daniels, Joe Parkin
|
|
|
|
1 |
p. e13
|
artikel
|
| 43 |
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population
|
Miners, Alec
|
|
2014
|
|
1 |
p. e32-e40
nvt p.
|
artikel
|
| 44 |
HIV combination prevention and declining orphanhood among adolescents, Rakai, Uganda, 2001–18: an observational community cohort study
|
Santelli, John S
|
|
|
|
1 |
p. e32-e41
|
artikel
|
| 45 |
HIV criminalisation laws and ending the US HIV epidemic
|
Mermin, Jonathan
|
|
|
|
1 |
p. e4-e6
|
artikel
|
| 46 |
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
|
Bhaskaran, Krishnan
|
|
|
|
1 |
p. e24-e32
|
artikel
|
| 47 |
HIV on the fast-track to sustainability
|
The Lancet HIV,
|
|
2016
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 48 |
HIV prevention cascades: a unifying framework to replicate the successes of treatment cascades
|
Schaefer, Robin
|
|
2019
|
|
1 |
p. e60-e66
|
artikel
|
| 49 |
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
|
Persaud, Deborah
|
|
|
|
1 |
p. e20-e30
|
artikel
|
| 50 |
HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report
|
Frange, Pierre
|
|
2016
|
|
1 |
p. e49-e54
nvt p.
|
artikel
|
| 51 |
Hope of post-treatment control after perinatal infection?
|
Rabie, Helena
|
|
2016
|
|
1 |
p. e6-e8
nvt p.
|
artikel
|
| 52 |
90-90-90: how do we get there?
|
McMahon, James H
|
|
2014
|
|
1 |
p. e10-e11
nvt p.
|
artikel
|
| 53 |
Immunological and virological findings in a patient with exceptional post-treatment control: a case report
|
Climent, Núria
|
|
|
|
1 |
p. e42-e51
|
artikel
|
| 54 |
Implied consent for HIV testing in the UK: time for a new approach?
|
Chadwick, David R
|
|
|
|
1 |
p. e63-e66
|
artikel
|
| 55 |
Improving outcomes for children in families with HIV
|
Gladstone, Melissa
|
|
|
|
1 |
p. e6-e7
|
artikel
|
| 56 |
Inherited fear: 40 years of HIV/AIDS in the UK
|
Lucas, Cathy
|
|
|
|
1 |
p. e14
|
artikel
|
| 57 |
Initial implementation of HIV pre-exposure prophylaxis for people who are incarcerated in Zambia: a cross-sectional observational study
|
Lindsay, Brianna
|
|
|
|
1 |
p. e24-e32
|
artikel
|
| 58 |
Intergenerational dialogue on HIV and ageing
|
The Lancet HIV,
|
|
|
|
1 |
p. e1
|
artikel
|
| 59 |
Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis
|
Kanters, Steve
|
|
2017
|
|
1 |
p. e31-e40
nvt p.
|
artikel
|
| 60 |
Introducing optimism to models of resource allocation to reduce HIV incidence
|
Williams, Brian G
|
|
2017
|
|
1 |
p. e12-
1 p.
|
artikel
|
| 61 |
Introducing optimism to models of resource allocation to reduce HIV incidence – Authors' reply
|
McGillen, Jessica B
|
|
2017
|
|
1 |
p. e12-
1 p.
|
artikel
|
| 62 |
Isange One Stop Centre: sanctuary from violence in Rwanda
|
Cousins, Sophie
|
|
2019
|
|
1 |
p. e12
|
artikel
|
| 63 |
Is it time to revise the notion that HIV-2 is benign?
|
Wejse, Christian
|
|
2019
|
|
1 |
p. e3-e4
|
artikel
|
| 64 |
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data
|
Ross, Jennifer M
|
|
|
|
1 |
p. e8-e15
|
artikel
|
| 65 |
Keeping HIV on the political agenda
|
The Lancet HIV,
|
|
|
|
1 |
p. e1
|
artikel
|
| 66 |
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
|
Gupta, Samir K
|
|
|
|
1 |
p. e15-e23
|
artikel
|
| 67 |
Lenacapavir in first-line therapy
|
Orkin, Chloe
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 68 |
Lessons from dolutegravir and neural tube defects
|
Abrams, Elaine
|
|
|
|
1 |
p. e3-e4
|
artikel
|
| 69 |
Linkage to and engagement in HIV care in western Kenya: an observational study using population-based estimates from home-based counselling and testing
|
Genberg, Becky L
|
|
2015
|
|
1 |
p. e20-e26
nvt p.
|
artikel
|
| 70 |
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic
|
Auerbach, Judith D
|
|
|
|
1 |
p. e62-e68
|
artikel
|
| 71 |
Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study
|
Esbjörnsson, Joakim
|
|
2019
|
|
1 |
p. e25-e31
|
artikel
|
| 72 |
Looking beyond facilities to eliminate vertical transmission
|
Rosenberg, Nora E
|
|
|
|
1 |
p. e4-e5
|
artikel
|
| 73 |
Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study
|
Rabie, Helena
|
|
2019
|
|
1 |
p. e32-e42
|
artikel
|
| 74 |
Maintaining ART services during COVID-19 border closures: lessons learned in Namibia
|
Hans, Linea
|
|
|
|
1 |
p. e7
|
artikel
|
| 75 |
Maximising the benefits of home-based HIV testing
|
Ferrand, Rashida
|
|
2015
|
|
1 |
p. e4-e5
nvt p.
|
artikel
|
| 76 |
Multi-stakeholder consensus on a target product profile for an HIV cure
|
Lewin, Sharon R
|
|
|
|
1 |
p. e42-e50
|
artikel
|
| 77 |
New option for ART in patients with HIV on dialysis
|
Ambrosioni, Juan
|
|
2019
|
|
1 |
p. e2-e3
|
artikel
|
| 78 |
Novel antiretroviral agents and universal access to HIV care
|
Boyd, Mark A
|
|
2016
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 79 |
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
|
Rasmussen, Thomas A
|
|
2014
|
|
1 |
p. e13-e21
nvt p.
|
artikel
|
| 80 |
Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial
|
Gross, Robert
|
|
2015
|
|
1 |
p. e12-e19
nvt p.
|
artikel
|
| 81 |
Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis
|
Wedi, Chrystelle O O
|
|
2016
|
|
1 |
p. e33-e48
nvt p.
|
artikel
|
| 82 |
Phylogenetic insights into age-disparate partnerships and HIV
|
Grabowski, Mary Kathryn
|
|
2017
|
|
1 |
p. e8-e9
nvt p.
|
artikel
|
| 83 |
Point-of-care viral load testing and differentiated HIV care
|
Dorward, Jienchi
|
|
2018
|
|
1 |
p. e8-e9
|
artikel
|
| 84 |
PrEP: why we are waiting
|
Jansen, Maarten Paul Maria
|
|
2016
|
|
1 |
p. e11-e12
nvt p.
|
artikel
|
| 85 |
Progress and challenges in China's free ART programme
|
Zhang, Fujie
|
|
2019
|
|
1 |
p. e8-e9
|
artikel
|
| 86 |
Quality of life in chronic HIV infection
|
Pozniak, Anton
|
|
2014
|
|
1 |
p. e6-e7
nvt p.
|
artikel
|
| 87 |
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial
|
Limbada, Mohammed
|
|
|
|
1 |
p. e13-e23
|
artikel
|
| 88 |
Reaching the third 95 using community ART delivery models
|
Mubiana-Mbewe, Mwangelwa
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 89 |
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study
|
Daskalopoulou, Marina
|
|
2014
|
|
1 |
p. e22-e31
nvt p.
|
artikel
|
| 90 |
Rehabilitate UNAIDS to reflect HIV/AIDS community values
|
The Lancet HIV,
|
|
2019
|
|
1 |
p. e1
|
artikel
|
| 91 |
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial
|
Eron Jr, Joseph J
|
|
2019
|
|
1 |
p. e15-e24
|
artikel
|
| 92 |
Seeing the people in the percentages
|
The Lancet HIV,
|
|
|
|
1 |
p. e1
|
artikel
|
| 93 |
Self-control for harm reduction in chemsex
|
Platteau, Tom
|
|
|
|
1 |
p. e8
|
artikel
|
| 94 |
Sex, drugs, and HIV: let's avoid panic
|
Holt, Martin
|
|
2014
|
|
1 |
p. e4-e5
nvt p.
|
artikel
|
| 95 |
Sharing Scotland's HIV story through blood, sweat, and tears
|
Ranscombe, Peter
|
|
|
|
1 |
p. e10
|
artikel
|
| 96 |
Should kidney disease risk affect antiretroviral choice?
|
Post, Frank A
|
|
2016
|
|
1 |
p. e3-e5
nvt p.
|
artikel
|
| 97 |
Skin cancer risk in people living with HIV: a call for action
|
Reinhart, Jacob P
|
|
|
|
1 |
p. e60-e62
|
artikel
|
| 98 |
Socioeconomic empowerment in an acute HIV cohort
|
Phanuphak, Praphan
|
|
2018
|
|
1 |
p. e5-e6
|
artikel
|
| 99 |
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation
|
Csete, Joanne
|
|
|
|
1 |
p. e52-e61
|
artikel
|
| 100 |
Super early treatment for HIV acquired in utero
|
Van de Perre, Philippe
|
|
|
|
1 |
p. e3-e4
|
artikel
|
| 101 |
Survival by sex and HIV status in patients with anal cancer in the USA between 2001 and 2019: a retrospective cohort study
|
Shing, Jaimie Z
|
|
|
|
1 |
p. e31-e41
|
artikel
|
| 102 |
Tailoring biomedical interventions for key populations
|
Beyrer, Chris
|
|
2015
|
|
1 |
p. e8-e9
nvt p.
|
artikel
|
| 103 |
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk
|
Drechsler, Henning
|
|
|
|
1 |
p. e8-e9
|
artikel
|
| 104 |
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk – Authors' reply
|
Neesgaard, Bastian
|
|
|
|
1 |
p. e9-e10
|
artikel
|
| 105 |
Tentative first steps to eradicate latent HIV
|
Kent, Stephen J
|
|
2014
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 106 |
The case for an HIV cure and how to get there
|
Dybul, Mark
|
|
|
|
1 |
p. e51-e58
|
artikel
|
| 107 |
The case for pre-exposure prophylaxis in prison settings
|
Chimoyi, Lucy
|
|
|
|
1 |
p. e3-e4
|
artikel
|
| 108 |
The death of HIV long-term non-progression?
|
Redd, Andrew D
|
|
2014
|
|
1 |
p. e8-e9
nvt p.
|
artikel
|
| 109 |
The effect of ART on cervical cancer precursor lesions
|
de Vries, Henry J C
|
|
2018
|
|
1 |
p. e6-e8
|
artikel
|
| 110 |
The HOPE social media intervention for global HIV prevention in Peru: a cluster randomised controlled trial
|
Young, Sean D
|
|
2015
|
|
1 |
p. e27-e32
nvt p.
|
artikel
|
| 111 |
The hunt for red, December
|
The Lancet HIV,
|
|
2018
|
|
1 |
p. e1
|
artikel
|
| 112 |
The importance of replicating results from randomised trials
|
Farley, Tim
|
|
2016
|
|
1 |
p. e11-
1 p.
|
artikel
|
| 113 |
The importance of replicating results from randomised trials – Authors' reply
|
Kuhn, Louise
|
|
2016
|
|
1 |
p. e11-
1 p.
|
artikel
|
| 114 |
The Lancet HIV: a journal for a new era of AIDS
|
The Lancet HIV,
|
|
2014
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 115 |
The past and present violence of Rwanda's HIV epidemic
|
Cousins, Sophie
|
|
2019
|
|
1 |
p. e10-e11
|
artikel
|
| 116 |
The potential pitfalls of PrEP
|
Cottrell, Mackenzie L
|
|
2019
|
|
1 |
p. e6-e8
|
artikel
|
| 117 |
The power of peers at prison exit
|
Spaulding, Anne C
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 118 |
Timing of antiretroviral therapy in children with advanced HIV
|
Prendergast, Andrew J
|
|
2018
|
|
1 |
p. e2-e3
|
artikel
|
| 119 |
Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis
|
Uthman, Olalekan A
|
|
2017
|
|
1 |
p. e21-e30
nvt p.
|
artikel
|
| 120 |
Towards a universal second-line fixed-dose combination ART
|
Boyd, Mark A
|
|
2018
|
|
1 |
p. e3-e5
|
artikel
|
| 121 |
Transitional community adherence support for people leaving incarceration in South Africa: a pragmatic, open-label, randomised controlled trial
|
Mabuto, Tonderai
|
|
|
|
1 |
p. e11-e19
|
artikel
|
| 122 |
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study
|
de Oliveira, Tulio
|
|
2017
|
|
1 |
p. e41-e50
nvt p.
|
artikel
|
| 123 |
Treating young children co-infected with tuberculosis and HIV
|
Turkova, Anna
|
|
2019
|
|
1 |
p. e4-e6
|
artikel
|
| 124 |
Two decades fighting two pandemics
|
Makoni, Munyaradzi
|
|
|
|
1 |
p. e8-e9
|
artikel
|
| 125 |
Unlocking adherence: is gender the key?
|
Puskas, Cathy
|
|
2015
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 126 |
Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trial
|
Njuguna, Irene N
|
|
2018
|
|
1 |
p. e12-e22
|
artikel
|
| 127 |
Use of WHO paediatric weight-band dosing in drug labels
|
Jacobs, Tom G
|
|
|
|
1 |
p. e3-e4
|
artikel
|
| 128 |
Vertical HIV transmission within 18 months post partum among women on lifelong antiretroviral therapy for HIV in Dar es Salaam, Tanzania: a prospective cohort study
|
Lyatuu, Goodluck Willey
|
|
|
|
1 |
p. e33-e41
|
artikel
|
| 129 |
Wild-type HIV infection despite PrEP: a lot to learn from a case report
|
Olalla, Julián
|
|
2018
|
|
1 |
p. e10
|
artikel
|
| 130 |
Wild-type HIV infection despite PrEP: a lot to learn from a case report
|
Darcis, Gilles
|
|
2018
|
|
1 |
p. e10
|
artikel
|
| 131 |
Wild-type HIV infection despite PrEP: a lot to learn from a case report – Authors' reply
|
Hoornenborg, Elske
|
|
2018
|
|
1 |
p. e10-e11
|
artikel
|
| 132 |
Will President Trump protect his party's PEPFAR legacy?
|
The Lancet HIV,
|
|
2017
|
|
1 |
p. e1-
1 p.
|
artikel
|
Tijdschrift beschrijving